These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 10643714)

  • 1. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.
    Badger AM; Griswold DE; Kapadia R; Blake S; Swift BA; Hoffman SJ; Stroup GB; Webb E; Rieman DJ; Gowen M; Boehm JC; Adams JL; Lee JC
    Arthritis Rheum; 2000 Jan; 43(1):175-83. PubMed ID: 10643714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements.
    Bradbeer JN; Kapadia RD; Sarkar SK; Zhao H; Stroup GB; Swift BA; Rieman DJ; Badger AM
    Arthritis Rheum; 1996 Mar; 39(3):504-14. PubMed ID: 8607900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.
    Badger AM; Blake S; Kapadia R; Sarkar S; Levin J; Swift BA; Hoffman SJ; Stroup GB; Miller WH; Gowen M; Lark MW
    Arthritis Rheum; 2001 Jan; 44(1):128-37. PubMed ID: 11212150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function.
    Badger AM; Bradbeer JN; Votta B; Lee JC; Adams JL; Griswold DE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1453-61. PubMed ID: 8968371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
    Stolina M; Schett G; Dwyer D; Vonderfecht S; Middleton S; Duryea D; Pacheco E; Van G; Bolon B; Feige U; Zack D; Kostenuik P
    Arthritis Res Ther; 2009; 11(6):R187. PubMed ID: 20003323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653.
    Nishikawa M; Myoui A; Tomita T; Takahi K; Nampei A; Yoshikawa H
    Arthritis Rheum; 2003 Sep; 48(9):2670-81. PubMed ID: 13130488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation.
    Mourey RJ; Burnette BL; Brustkern SJ; Daniels JS; Hirsch JL; Hood WF; Meyers MJ; Mnich SJ; Pierce BS; Saabye MJ; Schindler JF; South SA; Webb EG; Zhang J; Anderson DR
    J Pharmacol Exp Ther; 2010 Jun; 333(3):797-807. PubMed ID: 20237073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats.
    Boyle DL; Jones TL; Hammaker D; Svensson CI; Rosengren S; Albani S; Sorkin L; Firestein GS
    PLoS Med; 2006 Sep; 3(9):e338. PubMed ID: 16953659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis.
    Badger AM; Blake SM; Dodds RA; Griswold DE; Swift BA; Rieman DJ; Stroup GB; Hoffman SJ; Gowen M
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1380-6. PubMed ID: 10565864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats.
    Yamamoto N; Sakai F; Yamazaki H; Kawai Y; Nakahara K; Okuhara M
    J Rheumatol; 1996 Oct; 23(10):1778-83. PubMed ID: 8895158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat.
    Haddad EB; Birrell M; McCluskie K; Ling A; Webber SE; Foster ML; Belvisi MG
    Br J Pharmacol; 2001 Apr; 132(8):1715-24. PubMed ID: 11309243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia.
    Barone FC; Irving EA; Ray AM; Lee JC; Kassis S; Kumar S; Badger AM; White RF; McVey MJ; Legos JJ; Erhardt JA; Nelson AH; Ohlstein EH; Hunter AJ; Ward K; Smith BR; Adams JL; Parsons AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):312-21. PubMed ID: 11160612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis.
    Campagnuolo G; Bolon B; Feige U
    Arthritis Rheum; 2002 Jul; 46(7):1926-36. PubMed ID: 12124878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory properties of a novel N-phenyl pyridinone inhibitor of p38 mitogen-activated protein kinase: preclinical-to-clinical translation.
    Hope HR; Anderson GD; Burnette BL; Compton RP; Devraj RV; Hirsch JL; Keith RH; Li X; Mbalaviele G; Messing DM; Saabye MJ; Schindler JF; Selness SR; Stillwell LI; Webb EG; Zhang J; Monahan JB
    J Pharmacol Exp Ther; 2009 Dec; 331(3):882-95. PubMed ID: 19720877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibitor of p38 mitogen-activated protein kinase inhibits lipopolysaccharide-induced interleukin-8 expression in human pulmonary vascular endothelial cells.
    Hashimoto S; Gon Y; Matsumoto K; Maruoka S; Takeshita I; Hayashi S; Asai Y; Jibiki I; Machino T; Horie T
    J Pharmacol Exp Ther; 2000 May; 293(2):370-5. PubMed ID: 10773004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis.
    Magari K; Miyata S; Nishigaki F; Ohkubo Y; Mutoh S; Goto T
    J Rheumatol; 2003 Oct; 30(10):2193-200. PubMed ID: 14528517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures.
    Badger AM; Roshak AK; Cook MN; Newman-Tarr TM; Swift BA; Carlson K; Connor JR; Lee JC; Gowen M; Lark MW; Kumar S
    Osteoarthritis Cartilage; 2000 Nov; 8(6):434-43. PubMed ID: 11069728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.
    Koufany M; Chappard D; Netter P; Bastien C; Weryha G; Jouzeau JY; Moulin D
    Arthritis Rheum; 2013 Dec; 65(12):3084-95. PubMed ID: 23982996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.
    Jackson JR; Bolognese B; Hillegass L; Kassis S; Adams J; Griswold DE; Winkler JD
    J Pharmacol Exp Ther; 1998 Feb; 284(2):687-92. PubMed ID: 9454815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.